BUZZ-Viking gains on detailed mid-stage data for liver disease drug

Reuters11-20 18:42

** Shares of Viking Therapeutics rise about 4% to $53.52 before the bell

** Drug developer presented final results from a mid-stage trial of its experimental liver disease drug, VK2809, at a medical conference

** Detailed data shows patients treated with the drug had a 44% to 57% improvement in fibrosis or scarring of liver tissue vs 34% for placebo

** Trial was testing the drug in patients with a serious fatty liver disease called non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH)

** Drug previously achieved its primary goal of reducing liver fat content in the study and helped patients achieve NASH resolution with no worsening of fibrosis - VKTX

** Data was impressive as it showed fibrosis benefit at the highest dose and MASH resolution across all doses - William Blair analysts

** As of last close, VKTX shares have nearly tripled YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment